Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study

Fig. 2

ROS1-rearranged NSCLCs had better objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS) with first-line crizotinib therapy than chemotherapy. A Distribution of various ROS1 fusions detected using NGS-based method in 235 patients with locally advanced to advanced disease who received first-line therapy. B Treatment outcomes of patients with ROS1-rearranged NSCLCs who received either chemotherapy (red) or crizotinib therapy (green) in the first-line setting. C, D Kaplan-Meier survival curves illustrating the significantly better PFS for patients with ROS1-rearranged NSCLC (D) who received crizotinib (green) as compared to those who received chemotherapy (red) in the first-line setting; and (E) who received crizotinib and had non-CD74 ROS1 fusions (green) as compared to those with single CD74-ROS1 (red). The risk table below summarizes the number of patients included per time point

Back to article page